10-Q quarterly report · filed Nov 13, 2026

Benitec Biopharma Inc. (BNTC) Q3 2026 10-Q Quarterly Report

Short answer

Benitec Biopharma Inc. (BNTC) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$13M
−44.2% YoY
EPS (diluted)
−$0.26
−18.2% YoY

Source: XBRL data from the Benitec Biopharma Inc. (BNTC) Q3 2026 10-Q on SEC EDGAR. USD.

Benitec Biopharma Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, no product sales; no YoY revenue comparison disclosed
  • Operating expenses $14.5M vs $9.8M YoY, R&D $8.6M vs $3.4M
  • R&D highest growth area, up from $3.4M to $8.6M; G&A $5.9M vs $6.4M
  • Cash $176M; operating cash use $3.6M vs $3.4M YoY
  • Continued losses expected; cash sufficient for at least twelve months, with clinical-development funding risks

Risk Factors

  • No material changes to previously disclosed risk factors in the fiscal 2026 Form 10-K
  • Significant carried-forward risks not detailed in this 10-Q section

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Benitec Biopharma Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.